Arance Fernandez AM et al. Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. ESMO 2020;Abstract LBA44.

Daud AI et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34(34):4102-9. Abstract

Daud AI et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 2016;126(9):3447-52. Abstract

Larkin J et al. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. ASCO 2021;Abstract 9505.

Lipson EJ et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). ASCO 2021;Abstract 9503.

Mujal AM, Krummel MF. Immunity as a continuum of archetypes. Science 2019;364(6435):28-9. Abstract

Tumeh PC et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 2017;5(5):417-24. Abstract